MyFinsight
Home
Blog
About
Back
Cash Flow
Nuvectis Pharma, Inc. (NVCT)
Nuvectis Pharma, Inc. (NVCT)
source: myfinsight.com
Proceeds from issuance of
common shares-Public...
$1,388K
(-91.06%↓ Y/Y)
Proceeds from issuance of
common shares-At...
$177K
(-90.62%↓ Y/Y)
Net cash provided by
financing activities
$1,561K
(-90.12%↓ Y/Y)
Canceled cashflow
$4K
(decrease)/increase in cash and cash
equivalents
-$2,970K
(-135.96%↓ Y/Y)
Canceled cashflow
$1,561K
Cost of share-based
payments
$1,709K
(-44.85%↓ Y/Y)
(decrease)/increase in accounts
payable
$489K
(-80.27%↓ Y/Y)
Decrease in employee
compensation and benefits
$183K
(138.53%↑ Y/Y)
Decrease in accrued
liabilities
$56K
(106.68%↑ Y/Y)
Increase in other current
assets
-$52K
(-137.14%↓ Y/Y)
Issuance costs-At Market
Offering
$4K
(-93.22%↓ Y/Y)
Net cash used in
operating activities
-$4,531K
(39.92%↑ Y/Y)
Canceled cashflow
$2,489K
Net loss
-$7,020K
(39.83%↑ Y/Y)
Back